Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trialsResearch in context

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trialsResearch in context

Summary: Background: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen recommended for HIV-1 treatment. The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegravir [DTG]/abacavir/lamivudine) and 1490 (vs DTG ...

Full description

Bibliographic Details
Main Authors: Paul E. Sax, José R. Arribas, Chloe Orkin, Adriano Lazzarin, Anton Pozniak, Edwin DeJesus, Franco Maggiolo, Hans-Jürgen Stellbrink, Yazdan Yazdanpanah, Rima Acosta, Hailin Huang, Jason T. Hindman, Hal Martin, Jared M. Baeten, David Wohl
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:EClinicalMedicine
Subjects:
Antiretroviral therapy
Integrase strand transfer inhibitor
Long-term
Renal safety
Bone safety
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023001682

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023001682

Similar Items